Prosecution Insights
Last updated: November 20, 2026
Application No. 18/336,321

INTRAVENOUS ARTERIAL COMPLIANCE RESTORATION

Non-Final OA §103§112
Filed
Jun 16, 2023
Priority
Dec 18, 2020 — provisional 63/199,324 +2 more
Examiner
DIETRICH, JOSEPH M
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Edwards Lifesciences Corporation
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
770 granted / 949 resolved
+11.1% vs TC avg
Moderate +9% lift
Without
With
+8.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
44 currently pending
Career history
1006
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
13.2%
-26.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 949 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Invention I (claims 1 – 13) in the reply filed on 16 January 2026 is acknowledged. Claims 14 – 32 have been canceled. Newly presented claims 33 – 51 are directed to a method of shunting blood and are drawn to elected invention. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7, 34, 35, and 38 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 7 recites “further comprising: forming a third opening… provides access between the first blood vessel and the second blood vessel through the second opening. It is believed this should read “the third opening.” Claims 34 and 35 recites the limitation "the first port structure". There is insufficient antecedent basis for this limitation in the claim. These claims depend upon claim 33 which recites “anchoring a first port of a compliant fluid container.” It is unclear if the port structure recites in claims 34 and 35 refers to the first port in its entirety, if it is only a specific part of the first port, or if it is a different structure entirely. Claim 38 is unclear. It should read The method of claim 33. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1 – 13, 33 – 40, and 44 – 51 is/are rejected under 35 U.S.C. 103 as being unpatentable over Brenneman et al. (US PGPUB 2010/0268316) in view of Bak-Boychuk et al. (US PGPUB 2017/0246436 – in IDS). Regarding claim 1, Brenneman discloses a method of shunting blood, the method comprising: forming a first opening in a wall of a first blood vessel and a wall of a second blood vessel (e.g. ¶ 68); anchoring a first port of a compliant fluid container to the wall of the first blood vessel such that the first port provides access between the first blood vessel and the second blood vessel through the first opening (e.g. ¶ 74-76); but fails to teach placing a body of the compliant fluid container within the second blood vessel. Bak-Boychuk teaches it is known to use a stent-like anchor structure and to place it in a vein (e.g. ¶ 64). It would have been obvious to one having ordinary skill in the art to modify the invention as taught by Brenneman with the placement in the vein, since such a modification would provide the predictable results of allowing the chamber to reside in the low pressure vein allowing it to expand without occupying an arterial lumen. Regarding claim 2, Brenneman discloses the first blood vessel is an artery; and the second blood vessel is a vein (e.g. ¶ 8, 68). Regarding claim 3, Brenneman discloses channeling blood from the first blood vessel into the body of the compliant fluid container within the second blood vessel through the first port (e.g. ¶ 8, 76). Regarding claims 4 – 6, Brenneman discloses forming a second opening in the wall of the first blood vessel and the wall of the second blood vessel; anchoring a second port of the compliant fluid container to the wall of the first blood vessel such that the second port provides access between the first blood vessel and the second blood vessel through the second opening; and channeling blood from the body of the compliant fluid container into the first blood vessel through the second port (e.g. ¶ 68; multiple sites are considered – aorta/IVC and iliac/femoral). Regarding claim 7 - 10, neither Brenneman nor Bak-Boychuk explicitly recite the third port. However, both teach multiple sites. Adding a third port would be a mere duplication of parts. A duplication of parts has no patentable significance unless a new and unexpected result is produced. Regarding claims 11 and 12, Brenneman discloses the first port is formed by an anchoring structure of the compliant fluid container that is disposed within the first opening (e.g. ¶ 69 – 72). Bak-Boychuk teaches a stent as previously discussed (e.g. ¶ 64). Regarding claims 13, Brenneman discloses adding compliance to the first blood vessel by filling the body of the compliant fluid container with blood from the first blood vessel to thereby expand the body of the compliant fluid container within the second blood vessel (e.g. ¶ 8). Regarding claim 33, Brenneman in view of Bak-Boychuk disclose the method as discussed in claim 1 above. Furthermore, Brenneman discloses adding compliance to the first blood vessel by filling the body of the compliant fluid container with blood from the first blood vessel to thereby expand the body of the compliant fluid container within the second blood vessel (e.g. ¶ 8). Regarding claim 34, Brenneman discloses the first port structure comprises a metallic stent frame (e.g. ¶ 9, 69; nitinol tube). Regarding claim 35, Brenneman discloses a flange for anchoring the first port to the passageway (e.g. ¶ 70 – 72). Regarding claim 36, Brennaman discloses fluid is allowed to pass from the interior of the compliant fluid container and back into the arterial blood vessel through a second port (e.g. ¶ 68). Regarding claim 37, Brennaman discloses the first and second ports , but ails to teach one-way valves. Bak-Boychuk teaches it is known to use one-way valves in blood flow (e.g. ¶ 7). It would have been obvious to one having ordinary skill in the art to modify the device as taught by Brennaman with the one-way valves as taught by Bak-Boychuk, since such a modification would provide the predictable results of only allowing the blood to flow in the desired direction. Regarding claim 38, Brennaman discloses the compliant fluid container has a substantially tubular shape (e.g. ¶ 9). Regarding claims 39 and 40, Brenneman discloses the compliant fluid container is expandable (e.g. ¶ 9, 71) and the compliant fluid container has a sleeve disposed thereon (e.g. ¶ 13). Regarding claims 44 – 49, Brenneman discloses the arterial blood vessel is a descending aorta (e.g. ¶ 68) and the venous blood vessel is an inferior vena cava (e.g. ¶ 8, 68). Allowable Subject Matter Claims 41 – 43 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: The prior art fails to teach that a cross-section of the sleeve transitions from a non-circular shape to a more circular shape under increased blood pressure. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Lenihan et al. (US PGPUB 2015/0366580) teaches a tubular covered prosthesis implanted in the vein after an artery to vein connection. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH M DIETRICH whose telephone number is (571)270-1895. The examiner can normally be reached Mon - Fri 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH M DIETRICH/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797612
GAIT AND BALANCE ASSISTIVE STIMULATION DEVICE
3y 11m to grant Granted Nov 17, 2026
Patent 12797605
Compliance Voltage Monitoring and Adjustment in an Implantable Medical Device
2y 6m to grant Granted Nov 17, 2026
Patent 12796947
SMART RING FOR MEASURING BIOMETRIC SIGNAL
2y 8m to grant Granted Nov 17, 2026
Patent 12788676
Implantable Electroacupuncture System and Method
3y 4m to grant Granted Nov 10, 2026
Patent 12788316
IMPLANTABLE RF SENSOR FOR BIOFILM DETECTION
3y 1m to grant Granted Nov 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+8.9%)
3y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 949 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month